Sinofn Health
In the competitive landscape of global nutraceuticals, SINOFN Health stands as a bridge between cutting-edge research and commercial scalability. Founded on the bedrock of the Chinese Academy of Sciences (CAS), our manufacturing philosophy transcends basic OEM services. We offer "Information Gain"—providing our partners not just with products, but with regulatory foresight, formulation innovation, and supply chain security.
China is currently the global powerhouse for functional protein raw materials. The advantage lies in the integration of the upstream supply chain. SINOFN leverages this by securing high-purity inputs directly from the source, minimizing transit times, and implementing blockchain-enabled batch tracking. This ensures that every gram of protein—from whey peptides to plant-based isolates—maintains its bioavailability and structural integrity through the entire production cycle.
Modern global brands face a tripartite challenge: Clean Label demands, Formulation Complexity, and Regulatory Agility. SINOFN solves these through macro-industry solutions:
Experience (E): With a legacy tracing back to 2012 and the visionary leadership of Mrs. GuoHong Liu, we have deep-rooted experience in metabolic disorder formulations, specifically PKU (Phenylketonuria) dietary management.
Expertise (E): Our R&D center is not just a lab; it is an incubator. Dr. Tan Shengjie and Hans van Dijk lead a cross-continental team combining Eastern clinical knowledge with EU regulatory expertise in nutraceutical delivery systems.
Authoritativeness (A): Backed by the Chinese Academy of Sciences, our intellectual property portfolio—including 11 invention patents and 71 trademarks—establishes us as a Tier-1 innovator in the sector.
Trustworthiness (T): ISO 22000, HACCP, FSSC 22000, and Halal certifications are merely the baseline. Our real trust signal is our commitment to "Profit with Purpose," where revenues support critical PKU initiatives.
We utilize pilot-scale prototyping. Brands can test formulations in small batches to validate market fit before committing to full-scale production, ensuring capital efficiency.
Due to our in-house R&D and rapid raw material procurement, we typically compress standard industry R&D lead times by 30%, moving from concept to COA-verified sample in record time.